254 related articles for article (PubMed ID: 28615518)
21. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
Han HS; Yu E; Song JY; Park JY; Jang SJ; Choi J
Mol Cancer Res; 2009 May; 7(5):713-23. PubMed ID: 19435816
[TBL] [Abstract][Full Text] [Related]
22. Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2.
Abe Y; Oda-Sato E; Tobiume K; Kawauchi K; Taya Y; Okamoto K; Oren M; Tanaka N
Proc Natl Acad Sci U S A; 2008 Mar; 105(12):4838-43. PubMed ID: 18359851
[TBL] [Abstract][Full Text] [Related]
23. Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells.
Qiu W; Wu J; Walsh EM; Zhang Y; Chen CY; Fujita J; Xiao ZX
Oncogene; 2008 Jul; 27(29):4034-43. PubMed ID: 18332869
[TBL] [Abstract][Full Text] [Related]
24. MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation.
Shostak K; Patrascu F; Göktuna SI; Close P; Borgs L; Nguyen L; Olivier F; Rammal A; Brinkhaus H; Bentires-Alj M; Marine JC; Chariot A
Cell Death Differ; 2014 May; 21(5):811-24. PubMed ID: 24488098
[TBL] [Abstract][Full Text] [Related]
25. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells.
Dinda S; Sanchez A; Moudgil V
Oncogene; 2002 Jan; 21(5):761-8. PubMed ID: 11850804
[TBL] [Abstract][Full Text] [Related]
26. Heavy ion radiation-induced DNA damage mediates apoptosis via the Rpl27a-Rpl5-MDM2-p53/E2F1 signaling pathway in mouse spermatogonia.
Li H; Zhang H; Huang G; Dou Z; Xie Y; Si J; Di C
Ecotoxicol Environ Saf; 2020 Sep; 201():110831. PubMed ID: 32535367
[TBL] [Abstract][Full Text] [Related]
27. Estradiol agonists inhibit human LoVo colorectal-cancer cell proliferation and migration through p53.
Hsu HH; Kuo WW; Ju DT; Yeh YL; Tu CC; Tsai YL; Shen CY; Chang SH; Chung LC; Huang CY
World J Gastroenterol; 2014 Nov; 20(44):16665-73. PubMed ID: 25469035
[TBL] [Abstract][Full Text] [Related]
28. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
29. Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs.
Dolfi SC; Jäger AV; Medina DJ; Haffty BG; Yang JM; Hirshfield KM
Cancer Lett; 2014 Aug; 350(1-2):52-60. PubMed ID: 24747123
[TBL] [Abstract][Full Text] [Related]
30. Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells.
Brew CT; Aronchik I; Hsu JC; Sheen JH; Dickson RB; Bjeldanes LF; Firestone GL
Int J Cancer; 2006 Feb; 118(4):857-68. PubMed ID: 16152627
[TBL] [Abstract][Full Text] [Related]
31. Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.
Lu J; McEachern D; Li S; Ellis MJ; Wang S
Mol Cancer Ther; 2016 Dec; 15(12):2887-2893. PubMed ID: 27765850
[TBL] [Abstract][Full Text] [Related]
32. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
34. MDM2 regulates estrogen receptor α and estrogen responsiveness in breast cancer cells.
Kim K; Burghardt R; Barhoumi R; Lee SO; Liu X; Safe S
J Mol Endocrinol; 2011 Apr; 46(2):67-79. PubMed ID: 21169420
[TBL] [Abstract][Full Text] [Related]
35. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
36. Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression.
Schmitz KJ; Grabellus F; Callies R; Wohlschlaeger J; Otterbach F; Kimmig R; Levkau B; Schmid KW; Baba HA
Virchows Arch; 2006 Jan; 448(1):16-23. PubMed ID: 16208531
[TBL] [Abstract][Full Text] [Related]
37. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells.
Hu W; Feng Z; Ma L; Wagner J; Rice JJ; Stolovitzky G; Levine AJ
Cancer Res; 2007 Mar; 67(6):2757-65. PubMed ID: 17363597
[TBL] [Abstract][Full Text] [Related]
38. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
39. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.
Ou WB; Zhu J; Eilers G; Li X; Kuang Y; Liu L; Mariño-Enríquez A; Yan Z; Li H; Meng F; Zhou H; Sheng Q; Fletcher JA
Oncotarget; 2015 Apr; 6(12):10510-20. PubMed ID: 25888633
[TBL] [Abstract][Full Text] [Related]
40. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
